Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer...
Transcript of Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer...
![Page 1: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/1.jpg)
Precision Oncology & Pediatric Clinical Trials
Rebecca Deyell MD
Pediatric Hematology/Oncology
BC Children’s Hospital
November 2&3, 2018
![Page 2: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/2.jpg)
Overview
• Pediatric (&AYA) precision oncology in Canada
• A shifting paradigm: Molecularly targeted clinical trials in pediatrics
• One patient’s story
![Page 3: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/3.jpg)
![Page 4: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/4.jpg)
Pediatric Cancers: Survival at Relapse
Dr. Stefan Pfister, DKFZ, Heidelberg
![Page 5: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/5.jpg)
Question 1
Over the past decade, what has been true for MOST pediatric oncology early phase clinical trials?
A. Include a specific tumour type, aim to identify maximum tolerated dose and have objective response rates (ORR) >20%
B. Include many tumour types, aim to identify biologically effective dose, have ORR >10%
C. Include many tumour types, aim to identify maximum tolerated dose and have ORR <10%
D. Include a specific tumour type, aim to identify biologically effective dose and have ORR >20%
E. Include many tumour types with a specific genomic target, aim to identify maximum tolerated dose and have RR ~80% RESULTS
![Page 6: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/6.jpg)
POGO 2018
• More recent meta-analysis of pediatric phase Is (2004-2015)
shows similar ORR ~10% - ONLY 3% in solid tumours*
*Waligora et al. PLOS Med, 2018.
![Page 7: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/7.jpg)
Populations within a type of cancer
![Page 8: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/8.jpg)
El Kwak. NEJM 2010
![Page 9: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/9.jpg)
Precision Oncogenomics
Oncology consult & consentBiopsy (Metastatic site)
Pathology reviewSample preparation
Tumour (80x)Normal (40x)RNA (200M)
Targeted alignment analysis
WGS / WTS sequencing
Sample acquisition
Informed consent
‘In silico panel’ report
Clinical action
Follow up consult & clinical decision
Tumour board discussion
Review of genomic findingsDiscussion of potential for
clinical action
Integrative analysis
Genomic events of potential biological and therapeutic relevance
(in context to patient disease)
Genomic data generation
SNV, CNV, SVExpression
Other analyses
![Page 10: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/10.jpg)
POGO 2018
![Page 11: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/11.jpg)
![Page 12: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/12.jpg)
Modelsof
CAYACancers
Molecular Profiling&
Precision MedicineClinical Trials
Biospecimen
Canadian CAYA
CancerBiobank
&
Data Repository
• Discover New Targets• Develop Therapies• Understand Biology
Efficacy of Precision Medicine
IMPROVE OUTCOMESFOR HARD-TO-TREAT
CAYA CANCERS
Children, Adolescents, and Young Adults (CAYA) with Hard-to-Treat Cancers
• Biomarkers of Response• New Profiling Tools • Fuel Future Discoveries
![Page 13: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/13.jpg)
Question 2Precision Oncogenomics in Pediatrics
Which of the following best reflects our current understanding of the genomics of pediatric cancers?
a) Pediatric cancers have a higher mutation burden overall compared to adult cancers
b) Transcriptome data is routinely used in pediatrics to guide targeted therapy
c) Pediatric cancers frequently have oncogenic fusions
d) Germline analysis contributes little to our understanding of pediatric cancers
13
RESULTS
![Page 14: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/14.jpg)
Challenges in pediatric cancer
– Relatively rare, many with genome data n=1
– Few aberrations in the genome
– Hard to target driver events
14
GBMLGG
B-ALL
HL
BCL
NBLNeurofibrom
a
Osteosarcoma
CNS
Solid L&L
38 types of cancer from 72 pediatric POG patients
J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.
![Page 15: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/15.jpg)
Identify, screen, consent /assent
Tissue collection, pathology
review, Biobanking
Molecular Tumour
Profiling, Data
Analysis
Molecular Tumour Board
Quality Assurance and Ethics Oversight
PROFYLE CLINICAL NODE
Actionable Genomic
Finding(s)No actionable
Genomic Finding
≥12y
CAPTUR clinical
trial
CAPTUR pediatric
cohort
CAPTUR adult
cohort
CAPTUR
drugs
ALK inhibitor
PDGFR inhibitor
mTOR inhibitor
BRAF inhibitor
PARP inhibitor
SMO inhibitor
Health Canada
Open Label
Individualized
Patient Protocols
Compassionate /
SAP access
Pediatric phase
I/II trials
PR, CR, SD
PD
Continue therapy
Can-Pediatric
basket trial &
International
Collaborations
![Page 16: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/16.jpg)
Identify, screen, consent /assent
Tissue collection, pathology
review, Biobanking
Molecular Tumour
Profiling, Data
Analysis
Molecular Tumour Board
Quality Assurance and Ethics Oversight
PROFYLE CLINICAL NODE
Actionable Genomic
Finding(s)No actionable
Genomic Finding
≥12y <12y
CAPTUR clinical trial
CAPTUR pediatric
cohortCAPTUR adult
cohort
CAPTUR
drugs
ALK inhibitorPDGFR inhibitormTOR inhibitorBRAF inhibitorPARP inhibitorSMO inhibitor
Health Canada Individualized
Patient Protocols
Compassionate / SAP access
Pediatric phase I/II trials
PR, CR, SDPD
Continue therapy
Future PROFYLE basket trial
CAPTUR – Canadian Profiling & TargetedAgent Utilization Trial
![Page 17: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/17.jpg)
• Pan-Canadian trial to leverage national genomic profiling efforts and CCTG clinical trial capabilities
• Pharma partners: Committed to provide drug and funding
• Design modeled on, and linked to, US-TAPUR and Netherlands DRUP trials
CAPTUR
8 Patients
≥1x response?
<1x response?
+ 16 Patients
Stop cohort
≥5x response?
<5x response? Stop cohort
Further
investigation
![Page 18: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/18.jpg)
NCI Pediatric MATCH (APEC 1621)
![Page 19: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/19.jpg)
NCI Pediatric MATCH (APEC 1621)Drug Molecular Target Notes
Larotrectinib NTRK1/2/3 Prior Peds phase I
Erdafitinib FGFR1/2/3/4 No peds phase I*
Tazemetostat EZH2, SMARCB1, SMARCA4
Peds phase I ongoing
LY3023414 TSC1/2, PI3K/mTOR No peds data; Limited dose-finding phase (n=12)**
Selumetinib MEK Prior peds phase I
Ensartinib ALK, ROS1 No prior peds phase I*
Vemurafenib BRAF Ongoing pediatric study
Olaparib ATM, BRCA1/2, RAD51C/D
No peds data; limited dose-finding phase**
Palbociclib CDK4/6, CCND1/2/3 Ongoing pediatric phase Is
Ulixertinib NRAS, HRAS, KRAS, ARAF, BRAF, MAP2K1,GNAQ, MAPK1
No peds data; limited dose-finding phase**
POGO 2018
![Page 20: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/20.jpg)
NCI Pediatric MATCH (APEC 1621)
• Phase II Basket; marker-specific, histology-agnostic
• DNA/RNA panel approach
• Some non-commercially available drugs
• Some drugs without established pediatric phase I studies
• No combinations
POGO 2018
![Page 21: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/21.jpg)
ESMART(European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in
Relapsed/Refractory Tumours)
POGO 2018
Treatment Arm
Ribociclib & Topotecan/Temozolomide
Ribociclib & Everolimus
AZD1775 & Carboplatin
Olaparib & Irinotecan
Enasidenib
Lirilumab & Nivolumab
• (Phase I)/Phase II – ORR• R/R solid, CNS or leukemia• Opened in 2016 (ongoing)
![Page 22: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/22.jpg)
POGO 2018
![Page 23: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/23.jpg)
A Case from BC
• 13 year-old male
• Diagnosis: Papillary Thyroid Carcinoma– 11 years
– TNM Stage: T4aN1bM0
– Papillary Thyroid Carcinoma of right lobe, with extensive microscopic involvement of left lobe and isthmus, positive margins, extensive soft tissue invasion & positive nodes
• Treatment: – Initially received 100 millicuries of radioactive iodine (I131 RAI)
• Family history non-contributory; no prior radiation exposure
![Page 24: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/24.jpg)
Relapse
• 12 months later
– Thyroglobulin levels rising
– Relapse in neck, thyroid bed, paratracheal LNs and new bilateral pulmonary nodules
• Repeated OR for cervical debulking surgery and second 150mCi of I131-RAI.
• Repeat CT chest / neck 2 months later: rapid progression of innumerable pulmonary metastatic nodules.
24
![Page 25: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/25.jpg)
Case Presentation
• At the time of POG (2015)
– TNM Stage: TXN1bM1
– Biopsy sites: Bilateral and central neck compartments
– Biopsy again showed Papillary Thyroid Carcinoma
![Page 26: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/26.jpg)
POG results: Large structural variants
26
TPM3-NTRK1 fusion
A. Greco et al. Molecular and Cellular Endocrinology 321 (2010) 44–49
Wild type
Fusion
![Page 27: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/27.jpg)
Pediatric PTC
• More likely advanced / metastatic in children
• Recurrence rate is high – multiple ORs and RAI
• PTC – mutations and fusions in NTRK, RET, RAS and BRAF
• Children more often have fusion proto-oncogenes– NTRK1/3 fusions in up to 26% of pediatric PTC1
• At the time of POG presentation (2015) – no available NTRK inhibitor
• 2016 – Learned of preliminary adult phase I data for larotrectinib; open pediatric phase I study (in the US only)
271 Prasad et al. Cancer 122:1097-1107.
![Page 28: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/28.jpg)
28
![Page 29: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/29.jpg)
The “Trek” to Loxo101
• Lestaurtinib…
• The Endocrinologists
• Tumour Board
• Access to pediatric phase I studies out of country– BC Medical Services Plan
• Loxo Oncology and Seattle Children’s Hospital
29
![Page 30: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/30.jpg)
Case Conclusion
• Patient enrolled on Loxo101 (Pediatric Phase I of larotrectinib) in Seattle in Sept 2016
• Repeat CT chest/neck (post cycles 2, 4 & 6) showed resolution of almost all pulmonary nodules
• Excellent functional status, no therapy-related toxicity
• Still on study (cycle 28!)
• Larotrectinib pediatric phase I: 93% ORR among pediatric patients with TRK fusion cancers*– 0% ORR among 7 patients without TRK fusions
30*Laetsch et al. Lancet Oncol 2018; 19: 705–14
![Page 31: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/31.jpg)
Summary
• Changing paradigm of pediatric phase I/II trials in era of molecular targets
• Era of genomics = desperate need to translate targetable findings into clinical trials / new therapies
• Strategies to overcome challenges in our Canadian context
31
![Page 32: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/32.jpg)
![Page 33: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/33.jpg)
33
Questions?
![Page 34: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/34.jpg)
Clinical Trials Innovation In An Age of Precision Medicine
![Page 35: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/35.jpg)
Challenges With Clinical Trials
![Page 36: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/36.jpg)
Examples of Patient Roles In Addressing Challenges
Proposal to the Federal Minister of Health• Priority setting key part of building proposal• Ac2orn secured meeting with the Federal Minister of Health, the Honourable
Ginette Petitpas Taylor for April 2018• Support from numerous cancer organizations and about 30 individual Oncologists
from across North America• Follow up meeting with Health Canada in August and additional meeting planned
for DecemberPan Canadian Research Ethics BoardFeedback on Trial Design
![Page 37: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/37.jpg)
Back To Clinical Trials
• Phase I: Dose finding studies– Primary Objectives:
• Determine the Maximum Tolerated Dose and the Recommended Phase II dose • Describe the toxicity profile• Primary endpoint: Dose limiting toxicity
– Secondary Objectives:• Characterize pharmacokinetics (PK) and pharmacodynamic studies • Preliminary data on anti‐tumour activity (efficacy)• Correlative biology aims
![Page 38: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/38.jpg)
Definitions: Phase 2
• Phase II: First EFFICACY studies– Primary Objective:
• Determine anti‐tumour activity of novel agent(s)– Primary Endpoint: Objective response rate
– Based on disease re‐evaluations (Imaging, marrows, tumour markers)– Need MEASURABLE or EVALUABLE disease at study entry*
– Secondary Objectives:• Impact of therapy on survival outcomes (EFS, OS)• Further investigate pharmacokinetics and toxicity outcomes
![Page 39: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/39.jpg)
Looking Backwards To Change A Paradigm
![Page 40: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/40.jpg)
Finn
![Page 41: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/41.jpg)
My Perspective on Clinical Trials
![Page 42: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/42.jpg)
![Page 43: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/43.jpg)
![Page 44: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/44.jpg)
![Page 45: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/45.jpg)
To Change A Paradigm, We Have To Stop Confusing How We Do Clinical Trials With Why We Do Clinical Trials
![Page 46: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/46.jpg)
Confusing How With Why Leads to Compartmentalization
![Page 47: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/47.jpg)
Confusing How With Why Creates Challenges and Impedes Solutions
![Page 48: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/48.jpg)
We Have A Golden Opportunity To Shift A Paradigm
![Page 49: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/49.jpg)
We Need to Design With Challenges In Mind
• Time consuming, complicated, and expensive
• Historically getting pharmaceutical companies interested has been a challenge
• Funding, contracts, Health Canada, REBs, compliance, audits, paperwork
• Access – small studies, small networks, international collaboration
![Page 50: Precision Oncology & Pediatric Clinical Trials · Osteosarcoma CNS Solid L&L 38 types of cancer from 72 pediatric POG patients J Downing et.al, Nat Genet. 2012 May 29; 44(6): 619–622.](https://reader030.fdocuments.in/reader030/viewer/2022040800/5e34d093c5c5dc34446c183d/html5/thumbnails/50.jpg)
We Need to Design With Why In Mind